

PUTTING THE PIECES TOGETHER: INTERNATIONAL BEST PRACTICES IN ACCESS TO PHARMACEUTICAL INNOVATION

2008 Rx&D/IFPMA Policy Conference

Wednesday, May 28, 2008

Delta Hotel
Montreal, QC

Objectives

- To investigate and discuss health technology assessment as a means to improving access, reducing cost and improving patient outcomes;
- To cultivate research on access and pharmaceutical policy issues that can lead to informed policy-making; and,
- To develop an international network of researchers and experts who are engaged in evidence-based pharmaceutical policy research.

Time	Location	Topic
Wednesday, May 28, 2008		
7:30 – 8:30	2nd Floor Foyer	Registration and Breakfast Hot breakfast available for guests.
8:30 – 8:45	Opus 1/Opus 2	Introduction and Welcome Address <i>Ronnie Miller, Chairperson, Rx&D Board of Directors, will welcome participants and frame the conference objectives and the course of the day.</i>
8:45 – 9:30	Opus 1/Opus 2	Key Note Address Comparing Access and Outcomes: Findings from the 2008 Euro-Canada Health Consumer Index <i>Johan Hjertqvist, President, Health Consumer Powerhouse, Brussels/Stockholm and Rebecca Walberg, Director for Health Policy, Frontier Centre for Public Policy, Winnipeg will touch on the findings of a comparative benchmarking report that analyzes the consumer responsiveness of 29 health care systems from Europe and Canada, from their performance on patient rights and information to pharmaceutical access and outcomes.</i>
9:30 – 10:15	Opus 1/Opus 2	OECD: Pharmaceutical Pricing Policy in a Global Market <i>Elizabeth Docteur, OECD, will provide highlights and key findings from an upcoming OECD report on global pharmaceutical pricing in terms of the incentives for innovation created by various common policies and practices</i>

such as reference pricing and external benchmarking.

10:15 – 10:30	2nd Floor Foyer	Break
10:30 – 11:15	Opus 1/Opus 2	Access to Innovative Pharmaceuticals: How do Countries Compare? <i>George Wyatt, Wyatt Health Management, Toronto, Ontario</i> will release the findings of new research comparing the listing times of 15 OECD countries on a specific group of innovative pharmaceuticals.
11:15 – 12:00	Opus 1/Opus 2	Health Council of Canada – Health Care Reform and Patient Access <i>Donald Juzwishin, Chief Executive Officer, Health Council of Canada, Ottawa, Ontario</i>
12:00 – 1:00	Courtyard/Foyer	Networking Lunch Delegates can enjoy lunch in the courtyard.
1:00 – 1:45	Opus 1/Opus 2	International Models for Access to Innovative Pharmaceuticals <i>Professor John Bridges, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland</i> will discuss how countries involve patients and ensure accountability, transparency and fairness in their respective pharmaceutical assessment processes. Audience questions are encouraged.
1:45 – 3:00	Opus 1/Opus 2	Pharmaceutical Innovation Policies: International Examples from England and Canada Three case studies will be presented from England, Ontario and Quebec, highlighting how government policies have supported the environment for research and development. <i>Edward Bramley-Harker, PricewaterhouseCoopers, London, England</i> <i>Government of Quebec — TBC</i> <i>Government of Ontario — TBC</i>
3:00 – 3:15	2nd Floor Foyer	Break
3:15 – 4:00	Opus 1/Opus 2	Catastrophic Drug Coverage While medical conditions can be devastating to individuals and households, drug bills to treat these conditions can also be devastating. Speakers will address how their respective programs provide coverage to those patients that are not able to cover drug costs. Audience questions are encouraged. <i>John Abbott, Management Consultant, Institute for the Advancement of Public Policy, Inc., St. John's, Newfoundland</i>
4:00 – 4:15	Opus 1/Opus 2	Closing Remarks <i>Russell Williams, President, Canada's Research-Based Pharmaceutical Companies (Rx&D)</i>

